Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Endometrial Biopsy on in Vitro Fertilization Pregnancy Rates - a Randomized, Multicenter Study
Brief Summary: Animal and clinical studies have suggested that local tissue trauma can promote the process of an embryo implanting in the uterine cavity. The clinical studies have been performed in patients with a history of previously failed treatments using in vitro fertilization; a process of stimulating many eggs from a women and removing them from the body, to allow fertilisation with sperm to occur in a laboratory setting. The embryos are then replaced into the uterine cavity.

This study questions whether endometrial biopsy (placing a small straw like catheter through the cervix and into the uterine cavity to take a sample of tissue via suction into the bore of the catheter), within 5-10 days of starting a cycle of in vitro fertilization, will improve pregnancy outcome for patients in the first or second cycle of treatment. The hypothesis is that endometrial biopsy will improve pregnancy outcome.

The study is a randomized multicentre study involving 3 Canadian fertility centres.


Options:
A: Inclusion Criteria:

* primary or secondary infertility
* first or second IVF attempt
* aged ≥18 and ≤38 years
* regular menstrual cycles
* FSH≤ 12IU/L
* Informed consent signed

Exclusion Criteria:

* ovocyte donor
* pathology of the uterus or annexes
* Body mass index (BMI)\> 35
* ongoing vaginal infection
* undetermined vaginal bleeding
* contraindication to the Cornier pipette or to these treatments : Gonal F®, Puregon®, Ovitrelle®, Utrogestan®,
* women included in another study on medically assisted procreation
* any administrative or legal supervision
B: Inclusion Criteria:

* Undergoing IVF for tubal, unexplained or male factor subfertility
* Normal uterine cavity as shown on saline sonogram / hysteroscopy done at baseline

Exclusion Criteria:

* Presence of hydrosalpinx
* Presence of endometrial polyp or fibroid distorting uterine cavity
* IVF cycles carried out for preimplantation genetic diagnosis
* Use of donor gametes
C: Inclusion Criteria:

Women undergoing first or second IVF cycle, with or without ICSI

* Age 18-39
* BMI 18-35 kg/m2
* Uterine cavity evaluation (hysterosalpingogram, sonohysterogram, hysteroscopy) in the preceding 24 months
* Early follicular phase (Day 2 or Day 3) serum FSH, evaluated in the preceding 6 months

ONE of the following:

* Non- oral contraceptive pill (non-OCP) subjects: Documented LH surge 9-11 days prior to enrollment
* Current OCP subjects: OCP use for ≥ 10 days
* Use of long GnRH agonist or GnRH antagonist protocol
* Subject able to give informed consent

Exclusion Criteria:

* Prior enrolment in this study
* Any prior early follicular phase serum FSH level ≥12 IU/L
* Previous poor ovarian response, defined as prior IVF cycle cancelled for poor response, or ≤4 oocytes retrieved
* IVF for pre-implantation genetic diagnosis (PGD) or fertility preservation
* Diabetes mellitus or uncontrolled thyroid disease
* Abnormal uterine cavity, such as unresected submucosal fibroids, uterine septum, Mullerian anomaly such as bicornuate or unicornuate uterus or intrauterine adhesions
* Hydrosalpinx that has not been removed or surgically ligated
* Any contraindication to endometrial biopsy
* Office hysteroscopy or other uterine procedure planned or performed during cycle preceding IVF stimulation
* Use of surgically retrieved sperm
D: Inclusion Criteria:

* Patients are undergone intrauterine insemination with gonadotropin stimulation
* Bilateral patent fallopian tubes revealed by hysterosalpingography or laparoscopy
* After semen preparation for intrauterine insemination, total progressive sperm count \> 5 million

Exclusion Criteria:

* endocrin or metabolic disorders,
* uterine factor,
* pelvic inflammatory disease,
* women with basal follicle-stimulating hormone (FSH) level \>15 IU/mL,
* body mass index (BMI) ≥ 35 kg/m2,
* age ≥ 40 and \< 18 years,

Answer: C